Robert Zenenberg, DO
Nephrology · Florham Park, NJNPI 1245331834
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,632 of the $12,782 with a category attached, or 67.5%. 31 manufacturers reported payments, led by Travere Therapeutics, Inc. at 37.2% of the total. 2025 is the largest year on record at $5,618, 6.8 times the $824 reported in 2019. Among nephrology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 554 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$5K
- AstraZeneca$1K
- Vifor Pharma, Inc.$1K
- Amgen$1K
- GSK$847
- Otsuka America Pharmaceutical, Inc.$512
- plus $3K from 25 others
Across 4 payments — averaging $2076.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$8K
What the payments were for
- Consulting fees$3,60028%
- Travel & lodging$2782%
- Food & beverage$8,63268%
- Education$2732%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 41 | $4,756 |
| AstraZeneca(2 entities) | 91 | $1,432 |
| Vifor Pharma, Inc. | 79 | $1,218 |
| Amgen(2 entities) | 52 | $1,030 |
| GSK | 50 | $847 |
| Otsuka America Pharmaceutical, Inc. | 33 | $512 |
| OPKO Pharmaceuticals, LLC | 37 | $461 |
| Bayer | 16 | $237 |
| Arbor Pharmaceuticals, Inc. | 20 | $223 |
| Aurinia Pharma U.S., Inc. | 15 | $222 |
| Calliditas Therapeutics US Inc. | 16 | $216 |
| Ardelyx, Inc. | 13 | $210 |
| Daiichi Sankyo Inc. | 13 | $186 |
| Novartis | 10 | $155 |
| Sanofi | 10 | $154 |
| Novo Nordisk | 9 | $144 |
| Boehringer Ingelheim | 8 | $128 |
| Azurity Pharmaceuticals, Inc. | 7 | $112 |
| Fresenius USA Marketing, Inc. | 5 | $85 |
| Ultragenyx Pharmaceutical Inc. | 5 | $82 |
| Akebia Therapeutics Inc | 4 | $70 |
| ANI Pharmaceuticals, Inc. | 4 | $64 |
| Mallinckrodt Hospital Products Inc. | 4 | $58 |
| Invivyd Inc | 2 | $33 |
| Cormedix Inc. | 2 | $33 |
| Genentech USA, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $24 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
| Watermark Medical, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Strongbridge US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,782 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 241 | $207,139 |
| VeltassaPatiromer Calcium Sorbitex | 108 | $100,814 |
| EdarbiAzilsartan Medoxomil | 102 | $39,107 |
| LokelmaSodium Zirconium Cyclosilicate | 43 | $36,039 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 75 | $34,790 |
| JardianceEmpagliflozin | 36 | $34,248 |
| KerendiaFinerenone | 27 | $26,379 |
| Cinacalcet Hcl | 26 | $20,694 |
| Eplerenone | 143 | $16,138 |
| Paricalcitol | 86 | $7,660 |
| Telmisartan | 184 | $7,058 |
| Nebivolol Hcl | 57 | $4,011 |
| Clonidine | 12 | $3,067 |
| Telmisartan-HydrochlorothiazidTelmisartan/Hydrochlorothiazid | 49 | $3,037 |
| Torsemide | 199 | $2,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,432 | $243,178284 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $223 | $73,897177 claims |
| Boehringer IngelheimJardiance | $128 | $34,24836 claims |
| BayerKerendia | $237 | $26,37927 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $64 | $1,71741 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.
Other nephrology in Florham Park
- Jeffrey GoodmanFlorham Park$70K
- Kezia AlbertoFlorham Park$7K
- Seema KaranjgaokarFlorham Park$6K
- Lawrence ByrdLivingston$338K
- Jeffrey FeldmanUnion$315K
- Joshua KaplanNewark$154K
- Vadim FinkielsteinPrinceton Junction$139K
- Neeraj SinghNew Brunswick$133K
- Harry DounisNeptune$75K
- Kenneth LissEatontown$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.